Galectin Therapeutics Inc. (GALT)

Business: Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases.

IPO Date: 09-Sep-2002

Pres, CEO & Director: Mr. Joel Lewis

CFO, Treasurer & Sec.: Mr. Jack W. Callicutt CPA, CPA

Listing: NASDAQ: GALT

Country: United States

Headquarters: Norcross, GA

Website: https://galectintherapeutics.com

Market cap: $77.80 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-34.28 Mln

Cash: $31.61 Mln

Total Debt: $29.29 Mln

Insider's Holding: 38.79%

Liquidity: Low

52 Week range: $1.19 - 4.40

Shares outstanding: 59,388,500

10 Years Aggregate:

• CFO: $-142.63 Mln
• EBITDA: $-145.55 Mln
• Net Profit: $-176.44 Mln